Abstract
Background Accumulating evidence suggests that atorvastatin, a widely used lipid-lowering agent, may provide additional benefits for chronic obstructive pulmonary disease (COPD) patients, including anti-inflammatory effects and improved lung function. However, inconsistent findings across studies warrant a systematic evaluation to clarify its clinical role.
Objective To systematically evaluate the efficacy and safety of atorvastatin as an adjunctive treatment for COPD and inform clinical decision-making.
Methods A comprehensive search of PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, WanFang, CBM, and VIP databases identified randomized controlled trials (RCTs) up to May 20, 2024. Meta-analysis using RevMan 5.3 and R software was performed to estimate pooled effects with mean differences or standardized mean differences (95% CI). Subgroup analyses explored variations by treatment duration and dosage.
Results Twenty-four RCTs involving 2,534 patients demonstrated significant benefits of atorvastatin for stable COPD and acute exacerbations (AECOPD):Lung function: FEV1%pred increased by 5.36% (95% CI: 4.57–6.14), FEV1/FVC by 6.30% (95% CI: 4.46–8.14), and FEV1 by 0.21 L (95% CI: 0.15–0.27).Inflammatory markers: CRP decreased by 1.87 mg/L (95% CI: 1.45–2.29), with reductions in hs-CRP and IL-6.Quality of life: CAT scores improved by 3.5 points (95% CI: 2.8–4.2).Exercise capacity: The 6-minute walk distance increased by 25.4 meters (95% CI: 18.1– 32.7).Stronger evidence emerged with 3-month treatments (I² < 30%) and consistent benefits at 20 mg doses. Adverse events were mild and self-limiting.
Conclusion Atorvastatin (20 mg) significantly improves lung function, reduces inflammation, and enhances quality of life in COPD patients, with a favorable safety profile. Although not currently recommended in COPD guidelines, these findings support further trials to validate its potential role in COPD management.
Competing Interest Statement
The authors have declared that no competing interests exist
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This meta-analysis is based on publicly available data from the PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, WanFang, CBM, and VIP database, which was approved by the appropriate ethics committees of the original study. Informed consent was obtained from all participants in the original research
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data underlying the results presented in this meta-analysis were obtained through a comprehensive search of PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, WanFang, CBM, and VIP databases. The search was conducted up to May 20, 2024. The data analyzed in this study are from previously published studies, which are publicly available in the respective databases.
